Statement of Changes in Beneficial Ownership (4)
November 13 2015 - 4:38PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue.
See
Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
STARR KEVIN P
|
2. Issuer Name
and
Ticker or Trading Symbol
ALNYLAM PHARMACEUTICALS, INC.
[
ALNY
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__
X
__ Director
_____ 10% Owner
_____ Officer (give title below)
_____ Other (specify below)
|
(Last)
(First)
(Middle)
300 THIRD STREET
|
3. Date of Earliest Transaction
(MM/DD/YYYY)
11/11/2015
|
(Street)
CAMBRIDGE, MA 02142
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_
X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security
(Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code
(Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock
|
11/11/2015
|
|
M
(1)
|
|
25000.0
|
A
|
$9.3
|
25000
|
D
|
|
Common Stock
|
11/11/2015
|
|
M
(1)
|
|
12500.0
|
A
|
$11.33
|
37500
|
D
|
|
Common Stock
|
11/11/2015
|
|
S
(1)
|
|
2274.0
|
D
|
$105.3117
(2)
|
35226
|
D
|
|
Common Stock
|
11/11/2015
|
|
S
(1)
|
|
4027.0
|
D
|
$106.4611
(3)
|
31199
|
D
|
|
Common Stock
|
11/11/2015
|
|
S
(1)
|
|
12606.0
|
D
|
$107.3901
(4)
|
18593
|
D
|
|
Common Stock
|
11/11/2015
|
|
S
(1)
|
|
15499.0
|
D
|
$108.2258
(5)
|
3094
|
D
|
|
Common Stock
|
11/11/2015
|
|
S
(1)
|
|
3094.0
|
D
|
$109.1417
(6)
|
0
|
D
|
|
Common Stock
|
11/12/2015
|
|
M
(1)
|
|
12500.0
|
A
|
$11.33
|
12500
|
D
|
|
Common Stock
|
11/12/2015
|
|
M
(1)
|
|
25000.0
|
A
|
$15.82
|
37500
|
D
|
|
Common Stock
|
11/12/2015
|
|
S
(1)
|
|
35400.0
|
D
|
$100.0135
(7)
|
2100
|
D
|
|
Common Stock
|
11/12/2015
|
|
S
(1)
|
|
1200.0
|
D
|
$101.5825
(8)
|
900
|
D
|
|
Common Stock
|
11/12/2015
|
|
S
(1)
|
|
900.0
|
D
|
$103.0089
(9)
|
0
|
D
|
|
Table II - Derivative Securities Beneficially Owned (
e.g.
, puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 3)
|
2. Conversion or Exercise Price of Derivative Security
|
3. Trans. Date
|
3A. Deemed Execution Date, if any
|
4. Trans. Code
(Instr. 8)
|
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
6. Date Exercisable and Expiration Date
|
7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
|
8. Price of Derivative Security
(Instr. 5)
|
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)
|
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)
|
11. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
(A)
|
(D)
|
Date Exercisable
|
Expiration Date
|
Title
|
Amount or Number of Shares
|
Stock Option (right to buy)
|
$11.33
|
11/11/2015
|
|
M
(1)
|
|
|
12500.0
|
6/21/2013
(10)
|
6/21/2022
|
Common Stock
|
12500
|
$0.0
|
12500
|
D
|
|
Stock Option (right to buy)
|
$11.33
|
11/12/2015
|
|
M
(1)
|
|
|
12500.0
|
6/21/2013
(10)
|
6/21/2022
|
Common Stock
|
12500
|
$0.0
|
0
|
D
|
|
Stock Option (right to buy)
|
$15.82
|
11/12/2015
|
|
M
(1)
|
|
|
25000.0
|
6/2/2011
(10)
|
6/2/2020
|
Common Stock
|
25000
|
$0.0
|
0
|
D
|
|
Stock Option (right to buy)
|
$9.3
|
11/11/2015
|
|
M
(1)
|
|
|
25000.0
|
6/9/2012
(10)
|
6/9/2021
|
Common Stock
|
25000
|
$0.0
|
0
|
D
|
|
Explanation of Responses:
|
(
1)
|
The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 2, 2015.
|
(
2)
|
Sale prices ranged from $104.85 to $105.70.
|
(
3)
|
Sale prices ranged from $105.86 to $106.85.
|
(
4)
|
Sale prices ranged from $106.88 to $107.875.
|
(
5)
|
Sale prices ranged from $107.88 to $108.81.
|
(
6)
|
Sale prices ranged from $108.92 to $109.62.
|
(
7)
|
Sale prices ranged from $100.00 to $100.85.
|
(
8)
|
Sale prices ranged from $101.02 to $101.92.
|
(
9)
|
Sale prices ranged from $102.67 to $103.44.
|
(
10)
|
The option vested, in full, on the first anniversary of the Grant Date.
|
Reporting Owners
|
Reporting Owner Name / Address
|
Relationships
|
Director
|
10% Owner
|
Officer
|
Other
|
STARR KEVIN P
300 THIRD STREET
CAMBRIDGE, MA 02142
|
X
|
|
|
|
Signatures
|
By: /s/ Michael P. Mason, Attorney-In-Fact For: Kevin P. Starr
|
|
11/13/2015
|
**
Signature of Reporting Person
|
Date
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
|
*
|
If the form is filed by more than one reporting person,
see
Instruction 4(b)(v).
|
**
|
Intentional misstatements or omissions of facts constitute Federal Criminal Violations.
See
18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
|
Note:
|
File three copies of this Form, one of which must be manually signed. If space is insufficient,
see
Instruction 6 for procedure.
|
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
|
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Apr 2023 to Apr 2024